secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001104659-25-099740
Event type: leadership
Sentiment:  negative
Materiality: 0.90
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics terminates CEO (eff. Nov 15) and CSO; three directors resign
--------------------------------------------------------------------------------

- CEO Steven Kelly terminated without cause, effective Nov 15, 2025; gets $624K severance plus $299,948 prorated bonus and health payments.
- CSO Michael Klichinsky terminated without cause, effective Oct 15, 2025; receives 12 months salary in installments, prorated bonus, $2,245/month health payment.
- Directors John Hohneker, Briggs Morrison, David Scadden resigned Oct 15; Kelly resigns from board effective Nov 15.
- Company will appoint a consultant as CEO to manage wind-down; prior retention bonus agreement with Kelly voided.
- Wind-down of operations previously disclosed; no disagreement cited for director resignations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925099740/0001104659-25-099740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925099740/tm2528741d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-099740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer